Jacobs Levy Equity Management’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-16,635
Closed -$327K 965
2024
Q2
$327K Buy
+16,635
New +$333K ﹤0.01% 886
2024
Q1
Sell
-36,750
Closed -$1.01M 944
2023
Q4
$1.01M Sell
36,750
-55,329
-60% -$3.37M 0.01% 716
2023
Q3
$5.6M Sell
92,079
-12,467
-12% -$876K 0.03% 356
2023
Q2
$6.88M Buy
104,546
+36,950
+55% +$2.7M 0.04% 331
2023
Q1
$4.3M Buy
67,596
+29,839
+79% +$3.41M 0.03% 433
2022
Q4
$5.23M Buy
37,757
+31,396
+494% +$4.42M 0.04% 388
2022
Q3
$805K Sell
6,361
-226
-3% -$25.6K 0.01% 751
2022
Q2
$545K Sell
6,587
-13,146
-67% -$1.02M ﹤0.01% 856
2022
Q1
$1.91M Sell
19,733
-366
-2% -$48.3K 0.01% 629
2021
Q4
$4.02M Sell
20,099
-11,030
-35% -$2.6M 0.03% 475
2021
Q3
$7.71M Sell
31,129
-31,432
-50% -$8.99M 0.05% 352
2021
Q2
$25.9M Buy
62,561
+4,148
+7% +$1.64M 0.18% 156
2021
Q1
$22.8M Buy
58,413
+16,438
+39% +$8.09M 0.18% 151
2020
Q4
$23.5M Buy
41,975
+8,440
+25% +$5.35M 0.21% 118
2020
Q3
$23.4M Buy
33,535
+13,109
+64% +$10.2M 0.24% 105
2020
Q2
$16.1M Buy
20,426
+10,601
+108% +$7.99M 0.17% 143
2020
Q1
$5.85M Buy
+9,825
New +$9.57M 0.08% 267
2018
Q2
Sell
-103
Closed -$229K 1029
2018
Q1
$229K Buy
+103
New +$262K ﹤0.01% 901

Other funds holding BLUE

Jacobs Levy Equity Management's BLUE Position: Q3 2024 in Review

Jacobs Levy Equity Management sold out of bluebird bio (BLUE) in Q3 2024, closing a stake of 16,635 shares — an estimated $327K sold.

Jacobs Levy Equity Management first reported a position in BLUE in Q1 2018 and held it in 18 quarters. The position peaked at $25.9M in Q2 2021. 140 funds tracked by Wall St. Rank hold BLUE as of Q3 2024.

  • Jacobs Levy Equity Management reported no remaining bluebird bio position as of Q3 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 16,635 bluebird bio shares in Q3 2024, an estimated $327K.
  • Jacobs Levy Equity Management first reported a position in bluebird bio in Q1 2018 and held it in 18 quarters.
  • Jacobs Levy Equity Management's bluebird bio position peaked at $25.9M in Q2 2021.
  • 140 funds tracked by Wall St. Rank held bluebird bio as of Q3 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2024, filed 14 Nov 2024.